Watching the gorilla and questioning delivery dogma

被引：22
作者：
Anchordoquy, Thomas J. [1 ]
Simberg, Dmitri [1 ]
机构：
[1] Univ Colorado, Skaggs Sch Pharm & Pharmaceut Sci, Anschutz Med Campus, Aurora, CO 80045 USA
来源：
JOURNAL OF CONTROLLED RELEASE | 2017年 / 262卷
关键词：
RED-CELL APLASIA; PEGYLATED LIPOSOMAL DOXORUBICIN; HUMAN GROWTH-HORMONE; ANTI-PEG ANTIBODIES; DRUG-DELIVERY; COMPLEMENT ACTIVATION; SUSTAINED-RELEASE; RECOMBINANT ERYTHROPOIETIN; NEUTRALIZING ANTIBODIES; RHEUMATOID-ARTHRITIS;
D O I：
10.1016/j.jconrel.2017.07.021
中图分类号：
O6 [化学];
学科分类号：
0703 ;
摘要：
[No abstract available]
引用
收藏
页码：87 / 90
页数：4
相关论文
共 76 条
  • [71] Questioning the use of PEGylation for drug delivery
    Verhoef, Johan J. F.
    Anchordoquy, Thomas J.
    [J]. DRUG DELIVERY AND TRANSLATIONAL RESEARCH, 2013, 3 (06) : 499 - 503
  • [72] A comparison of liposomal formulations of doxorubicin with Drug Administered in free form: Changing toxicity profiles
    Waterhouse D.N.
    Tardi P.G.
    Mayer L.D.
    Bally M.B.
    [J]. Drug Safety, 2001, 24 (12) : 903 - 920
  • [73] An integrated assessment of morphology, size, and complement activation of the PEGylated liposomal doxorubicin products Doxil®, Caelyx®, DOXOrubicin, and SinaDoxosome
    Wibroe, Peter P.
    Ahmadvand, Davoud
    Oghabian, Mohammad Ali
    Yaghmur, Anan
    Moghimi, S. Moein
    [J]. JOURNAL OF CONTROLLED RELEASE, 2016, 221 : 1 - 8
  • [74] Development of antiinfliximab antibodies and relationship to clinical response in patients with rheumatoid arthritis
    Wolbink, GJ
    Vis, M
    Lems, W
    Voskuyl, AE
    de Groot, E
    Nurmohamed, MT
    Stapel, S
    Tak, PP
    Aarden, L
    Dijkmans, B
    [J]. ARTHRITIS AND RHEUMATISM, 2006, 54 (03): : 711 - 715
  • [75] ZHANG MZ, 1993, BIOPHYS J, V64, pA268
  • [76] Stabilization of proteins encapsulated in injectable poly (lactide-co-glycolide)
    Zhu, GZ
    Mallery, SR
    Schwendeman, SP
    [J]. NATURE BIOTECHNOLOGY, 2000, 18 (01) : 52 - 57
12345678